

Data Sheet

NAME :	vT183
REPOSITORY REFERENCE :	ARP2038
PROVIDED:	1 vial cell-free virus (NYCBH), 1.1×10^{10} pfu/ml
DESCRIPTION:	The HIV-1 _{92UG037.1} <i>env</i> gene was modified to introduce silent mutations to remove two internal T ₅ NT sequences encoding vaccinia virus early transcription termination sequences. A plasmid containing the vaccinia K1L gene and the modified <i>env</i> gene under control of the vaccinia 40K promoter was transfected into RK ₁₃ cells infected with vAbT33,aK1L-,M2L-,LacZ ⁺ derivative of the NYCBH strain that cannot grow on RK ₁₃ cells due to the absence of the K1L host range gene. The resultant recombinant, vT183, was isolated and purified in RK ₁₃ cells.
SPECIAL CHARACTERISTICS :	Cells infected with vT173 express the HIV-1 _{92UG037.1} <i>env</i> gene (subtype A).
STERILITY:	Negative for bacteria, fungi, and mycoplasma.
STORAGE :	-70°C
SOURCE :	Therion Biologics Corporation, in collaboration with Dr. Feng Gao and Dr. Beatrice Hahn. Viruses expanded by Quality Biological, Inc. (courtesy of NIH AIDS Research and reference Reagent Programme.)

NOTE:

Limited to 1 aliquot per laboratory. Recipients must maintain their own stocks according to the procedures described on the data sheet. Available only for non-commercial use. Requests from commercial institutions should be directed to Dr. Gail Mazzara, Vice President, R & D, Therion Biologics Corp., 76 Rogers St., Cambridge, MA02142

ACKNOWLEDGEMENTS :

Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website at <http://www.nibsc.ac.uk/spotlight/aidsreagent/index.html> in the "Acknowledgements" section.

Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)